🚀 VC round data is live in beta, check it out!
Vytrus Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vytrus Biotech and similar public comparables like Fortress Biotech, Gossamer Bio, Orexo, Citius Oncology and more.
Vytrus Biotech Overview
About Vytrus Biotech
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
Founded
2009
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$99M
Vytrus Biotech Financials
Vytrus Biotech reported last fiscal year revenue of $6M and EBITDA of $2M.
In the same fiscal year, Vytrus Biotech generated $6M in gross profit, $2M in EBITDA, and $1M in net income.
Revenue (LTM)
Vytrus Biotech P&L
In the most recent fiscal year, Vytrus Biotech reported revenue of $6M and EBITDA of $2M.
Vytrus Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $6M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 109% | XXX | XXX | XXX |
| EBITDA | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $1M | XXX | XXX | XXX |
| Net Margin | — | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vytrus Biotech Stock Performance
Vytrus Biotech has current market cap of $100M, and enterprise value of $99M.
Market Cap Evolution
Vytrus Biotech's stock price is $14.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $99M | $100M | -0.7% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVytrus Biotech Valuation Multiples
Vytrus Biotech trades at 17.1x EV/Revenue multiple, and 47.0x EV/EBITDA.
EV / Revenue (LTM)
Vytrus Biotech Financial Valuation Multiples
As of March 21, 2026, Vytrus Biotech has market cap of $100M and EV of $99M.
Equity research analysts estimate Vytrus Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vytrus Biotech has a P/E ratio of 85.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV (current) | $99M | XXX | $99M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 47.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 85.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 15.7x | XXX | XXX | XXX |
| P/E | — | XXX | 85.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 134.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vytrus Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vytrus Biotech Margins & Growth Rates
Vytrus Biotech's revenue in the last fiscal year grew by 35%.
Vytrus Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 56% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 89% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vytrus Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fortress Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Gossamer Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Orexo | XXX | XXX | XXX | XXX | XXX | XXX |
| Citius Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Gain Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vytrus Biotech M&A Activity
Vytrus Biotech acquired XXX companies to date.
Last acquisition by Vytrus Biotech was on XXXXXXXX, XXXXX. Vytrus Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vytrus Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVytrus Biotech Investment Activity
Vytrus Biotech invested in XXX companies to date.
Vytrus Biotech made its latest investment on XXXXXXXX, XXXXX. Vytrus Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vytrus Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vytrus Biotech
| When was Vytrus Biotech founded? | Vytrus Biotech was founded in 2009. |
| Where is Vytrus Biotech headquartered? | Vytrus Biotech is headquartered in Spain. |
| Is Vytrus Biotech publicly listed? | Yes, Vytrus Biotech is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Vytrus Biotech? | Vytrus Biotech trades under VYT ticker. |
| When did Vytrus Biotech go public? | Vytrus Biotech went public in 2022. |
| Who are competitors of Vytrus Biotech? | Vytrus Biotech main competitors are Fortress Biotech, Gossamer Bio, Orexo, Citius Oncology. |
| What is the current market cap of Vytrus Biotech? | Vytrus Biotech's current market cap is $100M. |
| What is the current revenue of Vytrus Biotech? | Vytrus Biotech's last fiscal year revenue is $6M. |
| What is the current EV/Revenue multiple of Vytrus Biotech? | Current revenue multiple of Vytrus Biotech is 17.1x. |
| Is Vytrus Biotech profitable? | No, Vytrus Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.